Przejdź do
L1920
LY255283
≥98% (HPLC), powder
Synonim(y):
1-(5-Ethyl-2-hydroxy-4-(6-methyl-6-(1H-tetrazol-5-yl)heptyloxy)phenyl)ethanone
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
| Gabaryty przesyłki | SKU | Dostępność | Cena netto |
|---|
Informacje o tej pozycji
Wzór empiryczny (zapis Hilla):
C19H28N4O3
Numer CAS:
Masa cząsteczkowa:
360.45
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352204
MDL number:
Aby zapytać o ten produkt L1920, skontaktuj się z lokalnym biurem lub sprzedawcą firmy Merck. Skontaktuj się z zespołem ds. pomocy technicznej
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócQuality Level
assay
≥98% (HPLC)
form
powder
color
off-white to light yellow
solubility
DMSO: >20 mg/mL
originator
Eli Lilly
storage temp.
−20°C
SMILES string
CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c2nnn[nH]2
InChI
1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)
InChI key
WCGXJPFHTHQNJL-UHFFFAOYSA-N
Application
LY255283, a competitive leukotriene B4 receptor antagonist, is used in leukotriene receptor research along with other selective leukotriene receptor agonists and antagonist to identify and differentiate the physiological and cell signaling effects of the leukotriene B4 receptor on processes such as paclitaxel resistance in MCF-7/DOX breast cancer cells, monocyte-derived dendritic cell chemotaxis, and 5-lipoxygenase activity and interleukin-8 production in human neutrophils.[1] LY255283 may be used to help verify that an observed process or cell event is leukotriene B4 receptor-dependent.[1]
Biochem/physiol Actions
LY255283 is a competitive leukotriene B4 receptor antagonist, specific to the BLT2 receptor subtype.
LY255283 is a competitive leukotriene B4 receptor antagonist, with an IC50 of about 100 nM. It is somewhat selective for the BLT2 receptor, since IC50 values at the BLT1 receptor are >10 μM. LY255283 reduces airway obstruction in animal models of asthma.
Features and Benefits
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Ta strona może zawierać tekst przetłumaczony maszynowo.
1 of 1
Ta pozycja | |||
|---|---|---|---|
| form powder | form solid | form powder | form powder |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. −20°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| solubility DMSO: >20 mg/mL | solubility DMSO: ≥20 mg/mL | solubility DMSO: 10 mg/mL, clear | solubility DMSO: 10 mg/mL, clear |
| originator Eli Lilly | originator GlaxoSmithKline | originator - | originator - |
Klasa składowania
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Produkty
Discover Bioactive Small Molecules for Lipid Signaling Research
D G Souza et al.
European journal of pharmacology, 403(1-2), 121-128 (2000-09-02)
Reperfusion of ischemic vascular beds may lead to recruitment and activation of leukocytes, release of mediators of the inflammatory process and further injury to the affected vascular bed and to remote sites. Neutrophils appear to play a major role in
Eun-Young Kim et al.
Free radical biology & medicine, 49(6), 1072-1081 (2010-07-06)
Aggressive bladder cancer is a major cause of morbidity and mortality. Despite the fact that metastatic disease results in death in the majority of bladder cancer cases, the molecular events regulating the invasive phenotype of aggressive bladder cancer are not
J S Sawyer et al.
Journal of medicinal chemistry, 38(22), 4411-4432 (1995-10-27)
Structural derivatives of LY255283 have been studied as receptor antagonists of leukotriene B4. Substitution of the 2-hydroxyacetophenone subunit of 1 (LY255283) with a 2-arylphenol group provided entry into several new series that feature various mono- and diacidic core functionality. These
Numer pozycji handlu globalnego
| SKU | NUMER GTIN |
|---|---|
| L1920-5MG | 04061833024263 |
| L1920-25MG | 04061833024256 |